Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | NOD1 | Q9Y239 | 4/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | GABRP | O00591 | 2/20 | 0.31 |
| ▸ | GABRD | O14764 | 2/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.31 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.31 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.31 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.31 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.31 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.31 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18477085 | 1.00 | CYP2D6 (0.38) | CYP2D6CYP2C9CYP2C19NOD1ALOX15 | |
| SCHEMBL24301935 | 0.84 | LTA4H (0.39) | NOD1ALOX15CYP1A2KMT2AGRM8 | |
| SCHEMBL18476661 | 0.82 | TSHR (0.39) | CYP2D6CYP2C9CYP2C19NOD1ALOX15 | |
| SCHEMBL18476697 | 0.81 | CYP2D6 (0.36) | CYP2D6CYP2C9CYP2C19NOD1ALOX15 | |
| SCHEMBL22354580 | 0.81 | GABRP (0.31) | CYP1A2GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL18476654 | 0.81 | GABRP (0.31) | CYP1A2GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL29341620 | 0.79 | LTA4H (0.40) | — | |
| SCHEMBL24305812 | 0.79 | TDP1 (0.34) | CYP2D6CYP2C19ALDH1A1KMT2AHSD17B10 | |
| SCHEMBL18452613 | 0.78 | FAAH (0.38) | CYP2D6CYP2C9CYP2C19NOD1ALOX15 | |
| SCHEMBL18476646 | 0.78 | FAAH (0.38) | CYP2D6CYP2C9CYP2C19NOD1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3328827-B1 | PRODRUGS OF GLUTAMINE ANALOGS | UNIV JOHNS HOPKINS (US) | 2023-07-05 | — | — | EP | disclosed |
| US-11110104-B2 | Glutamine antagonists for the treatment of cognitive deficits and psychiatric disorders | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-09-07 | — | — | US | disclosed |
| US-10954257-B2 | Prodrugs of glutamine analogs | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-03-23 | — | — | US | disclosed |
| US-10738066-B2 | Prodrugs of glutamine analogs | THE JOHNS HOPKINS UNIVERSITY (US) | 2020-08-11 | — | — | US | disclosed |
| US-20190315783-A1 | PRODRUGS OF GLUTAMINE ANALOGS | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), AS COLLATERAL AGENT | 2019-10-17 | — | — | US | disclosed |
| US-20190315784-A1 | PRODRUGS OF GLUTAMINE ANALOGS | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), AS COLLATERAL AGENT | 2019-10-17 | — | — | US | disclosed |
| US-10336778-B2 | Prodrugs of glutamine analogs | THE JOHNS HOPKINS UNIVERSITY (US) | 2019-07-02 | — | — | US | disclosed |
| US-20180222930-A1 | PRODRUGS OF GLUTAMINE ANALOGS | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), AS COLLATERAL AGENT | 2018-08-09 | — | — | US | disclosed |
| US-20180193362-A1 | GLUTAMINE ANTAGONISTS FOR THE TREATMENT OF COGNITIVE DEFICITS AND PSYCHIATRIC DISORDERS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2018-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10738066-B2 | Prodrugs of glutamine analogs | GLUL, GLS, GLS2 | CYP2D6 68/4885CYP2C9 316/4885CYP2C19 347/4885 |
| US-20180193362-A1 | GLUTAMINE ANTAGONISTS FOR THE TREATMENT OF COGNITIVE DEFICITS AND PSYCHIATRIC DISORDERS | GLUL, GLS2, SLC1A2 | CYP2D6 375/4885CYP2C9 1303/4885CYP2C19 697/4885 |
| US-20190315783-A1 | PRODRUGS OF GLUTAMINE ANALOGS | GLUL, GLS, GLS2 | CYP2D6 68/4885CYP2C9 316/4885CYP2C19 347/4885 |
| US-10336778-B2 | Prodrugs of glutamine analogs | GLUL, GLS, GLS2 | CYP2D6 68/4885CYP2C9 316/4885CYP2C19 347/4885 |
| US-10954257-B2 | Prodrugs of glutamine analogs | GLUL, GLS, GLS2 | CYP2D6 68/4885CYP2C9 316/4885CYP2C19 347/4885 |
| US-11110104-B2 | Glutamine antagonists for the treatment of cognitive deficits and psychiatric disorders | GLUL, GLS2, SLC1A2 | CYP2D6 375/4885CYP2C9 1303/4885CYP2C19 697/4885 |
| US-20180222930-A1 | PRODRUGS OF GLUTAMINE ANALOGS | GLUL, GLS, GLS2 | CYP2D6 68/4885CYP2C9 316/4885CYP2C19 347/4885 |
| US-20190315784-A1 | PRODRUGS OF GLUTAMINE ANALOGS | GLUL, GLS, GLS2 | CYP2D6 68/4885CYP2C9 316/4885CYP2C19 347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.